Drug Science, Policy and Law
September 1, 2025
David Nutt, David Erritzøe, Anne Katrin Schlag et al.
9 citations
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant depression and receiving fast-track or breakthrough designations from regulatory agencies. Despite this progress, the field lacks standardized terminology to guide clinical development, dosing, safety monitoring, and regulatory classification. Here,...
Frontiers in Psychiatry
September 1, 2025
Ronit Kishon, Yael M. Cycowicz
The resurgence of interest in psychedelic compounds as potential treatments for psychiatric disorders represents a paradigm shift in mental health care. Psychedelics exert their effects through serotonergic modulation, particularly via 5-HT2A receptor activation, inducing profound alterations in consciousness and catalyzing neuroplasticity. While their neurobiological effects are...
INTERdisciplina
August 30, 2025
Genlizzie Elizabeth Garibay Munguía
This article aims to understand how contemporary psychedelic capitalism, through medicalization, regulation, and commodification of ancestral psychoactive substances (such as psilocybin mushrooms, peyote, ayahuasca and others), reproduces dynamics of biopiracy and bioappropriation that exploit the territories, knowledge, and practices of indigenous communities. From a critical perspective...
Pharmaceutical Science
August 27, 2025
Guilllermo Castaño-perez, Sara Isabel Castaño-ocampo
The resurgence of research on the use of psychedelic substances for the treatment of mental disorders and addictions has generated significant interest in the scientific and clinical communities. This chapter examines the current evidence on the efficacy, safety, and limitations of psychedelics in the treatment of these conditions. Studies investigating the use of psychedelics as monotherapy...
medRxiv
August 27, 2025
Md. Shahidul Islam, Md Sakib Ibne Salam, Md Nahid Hasan
1 citation
preprint
A bstract Contemporary psychedelic research highlights the value of user experience reports, yet their verbose, subjective nature poses challenges for clinical utility. This is the first study to pioneer unsupervised automatic text summarization of psychedelic user experience reports, a domain where no human-annotated reference summaries exist. To address this gap, we developed a custom scoring...
Acta neurológica colombiana
August 26, 2025
Gianfranco Faccini-Durán
Introducción: la psilocibina, un alcaloide triptamínico presente en hongos genero psilocybe, actúa uniéndose a receptores serotoninérgicos de tipo 2A (5HT2A), activando respuestas metabotrópicas y resultando en procesos de neuroplasticidad. Se integran diversas metodologías de abordaje científico, incluyendo estudios pre clínicos y clínicos, sobre con los efectos neurofisiológicos, y el...
Molecular Psychiatry
August 23, 2025
Adam J. Drewko, Ron L. P. Habets, Tibor M Brunt
4 citations
Serotonergic psychedelics, including the recreationally used psilocybin and LSD, have become promising therapeutic agents for the treatment of treatment-resistant depression. While it is generally agreed that they exhibit their antidepressant effects by inducing rapid and sustained neuroplasticity, the molecular mechanisms responsible are widely debated. In particular, the role of the serotonin...
ACS Pharmacology & Translational Science
August 22, 2025
Devin P. Effinger, Serena S. Schalk, Jillian L. King et al.
3 citations
High Resolution Image Download MS PowerPoint Slide Microdosing, the prolonged ingestion of psychedelics at subhallucinogenic doses, has gained popularity for its perceived cognitive and emotional benefits. Psychedelics have high affinity for 5-HT 2B receptors, a receptor known to cause human heart disease with strong chronic activation. We investigated the effects of microdosed psychedelics on...
Research Square
August 22, 2025
Richard J. Zeifman, George Danias, Gabrielle Agin-Liebes et al.
2 citations
preprint
Abstract Background: Psychedelics can acutely induce mystical experiences and elevated positive mood, which may contribute to the potential benefits of psychedelic therapy. However, there remains limited understanding of the occurrence and importance of specific positive emotional experiences within psychedelic therapy. Therefore, we examined the effects of psychedelics on positive emotional...
NPP Digit Psychiatry Neurosci
August 20, 2025
Albert Garcia‐romeu
2 citations
Interest in “psychedelic therapies,” using substances such as ketamine, 3,4-methylenedioxymethamphetamine (MDMA), and psilocybin to treat psychiatric conditions, has grown steadily in recent years. Although pharmacologically distinct and functioning via differential mechanisms, these drugs are broadly classified as hallucinogenic, meaning they are thought to produce hallucinations. However,...